Type 2 Diabetes Mellitus Clinical Trial
Official title:
Insulin Sensitivity and Metabolomics During Oral Administration of Glucose and a Graded Intravenous Infusion in Patients With Normal Glucose Tolerance, Impaired Glucose Tolerance and in Patients With Type 2 Diabetes Mellitus
Bariatric surgery has been proven to be an effective treatment of type 2 diabetes and it has
highlighted to role of the small intestine in glucose homeostasis. Improvement of glucose
homeostasis occurs just a few days after the bariatric surgery, where parts of the small
intestine is bypassed, has been performed. Furthermore, conditioned medium from the duodenum
and the jejunum from both diabetic rodents and humans are able to induce insulin resistance
in normal mice and in myocytes. Hence the hypothesis is that the small intestine secretes
factors that are able to induce insulin resistance.
This project aims to study how orally ingested glucose is able to induce insulin resistance
and if this response differs in patients with normal glucose tolerance, impaired glucose
tolerance and in patients with type 2 diabetes mellitus. To address this question glucose
homeostasis will be studied by comparing whole body glucose uptake during a progressively
increased oral glucose load with a graded glucose infusion where the blood glucose levels
will be kept in the same range as during the oral glucose load in patients with normal
glucose tolerance, impaired glucose tolerance and patients with type 2 diabetes mellitus.
Previous studied have shown that different metabolites and bile acids could be involved the
regulation of glucose homeostasis. Hence, it is possible that the gut regulates metabolites
that could be involved in small intestine-induced insulin resistance described above. The aim
of this research is to study metabolomics in plasma collected during the oral glucose
tolerance test with increasing load of glucose and the graded glucose infusion where plasma
glucose level will be held in the same levels as during the oral glucose tolerance test and
study the differences in patients with normal glucose tolerance, impaired glucose tolerance
and in patients with type 2 diabetes mellitus.
The expected results in this study will demonstrate that the gut plays an important role in
glucose homeostasis and that this system is dysregulated in type 2 diabetes. More
importantly, novel factors derived or regulated from the gut that regulate insulin resistance
and glucose tolerance will be identified which could be possible targets for future
antidiabetic therapies.
The incidence of obesity and obesity-associated metabolic disorders such as insulin
resistance and type 2 diabetes is increasing worldwide. To date, bariatric surgery is the
only obesity treatment that results in long-term weight reduction. In addition, bariatric
surgery has been reported to promote remission of type 2 diabetes and to be a more effective
treatment than standard medication for type 2 diabetes. Surprisingly, improvement in glucose
homeostasis after some bariatric surgery procedures occurs before weight loss is achieved.
The mechanisms behind this improvement are still unclear but a recent study indicates that
the bypassing of jejunum could play an important role in glucose homeostasis. Moreover,
jejunum-derived proteins present in serum in both human and mice induce insulin resistance in
cell cultures of myocytes and in mice. This taken together indicates that the gut may play an
important role in glucose homeostasis in type 2 diabetes mellitus.
Metabolomics has recently been regarded to be one of the most suitable technologies for
investigating complex diseases such as type 2 diabetes mellitus because it represent a
real-time functional portrait of the organisms. Previous studies have shown that different
metabolites and bile acids could be involved in the regulation of glucose homeostasis. Hence
it is possible that the gut regulates metabolites that could be involved in the impaired
glucose tolerance and type 2 diabetes mellitus.
The specific aims of this research project are:
Aim 1: To demonstrate that orally ingested glucose induces insulin resistance and to
determine if this regulation of glucose homeostasis differs between subjects with normal
glucose tolerance, impaired glucose tolerance and subjects with type 2 diabetes mellitus.
Aim 2: To identify metabolites regulated by the gut that are associated with impaired glucose
tolerance and type 2 diabetes mellitus.
To address this aim, differences in glucose kinetics will be studied when glucose is orally
administrated (in an oral glucose tolerance test, OGTT) compared to an graded intravenous
glucose infusion, were plasma glucose levels are held in the same range as during the OGTT,
in subjects with normal glucose tolerance (n = 8), impaired glucose tolerance (n = 8) and
type 2 diabetes mellitus (n = 8).
Basal glucose kinetics will first be assessed by double glucose tracer technique. In the
basal part of the glucose tolerance tests glucose tracer nr 1 will be infused and then be
followed by either a continued infusion and a gradually increasing oral glucose load (25 g,
75 g and 125 g with a 2 h interval during the OGTT) with glucose tracer nr 2 or an graded
intravenous glucose tracer infusion where plasma glucose levels are adjusted to those
obtained during the OGTTs.
Gas chromatography/mass spectrometry will be used to measure isotopic enrichment of glucose
tracers. Insulin, glucagon, total glucagon-like peptide 1 (GLP-1) and C-peptide will be
measured by radioimmunoassays repeatedly during the glucose tolerance tests. Glucose kinetics
including endogenous glucose production, insulin sensitivity and insulin secretion will be
calculated. Differences in glucose kinetics between the oral and intravenous administration
of glucose will be calculated and compared in subjects with normal glucose tolerance,
impaired glucose tolerance or type 2 diabetes mellitus.
Analysis of metabolomics will be performed in plasma collected during the OGTT and the graded
intravenous glucose infusion. Metabolites in plasma samples will be analyzed using two global
profiling analytical platforms and a targeted profiling platform. Two-dimensional gas
chromatography coupled to time-of-flight mass spectrometry (GCxGC-TOFMS) will be performed to
measure small polar metabolites. Molecular lipids will be assessed by a global platform using
ultra performance liquid chromatography coupled to quadrupole-TOFMS (UPLC-QTOFMS). A targeted
platform based on UPLC coupled to triple-quadrupole MS (UPLC-QqQMS) will be performed to
quantify both unconjugated and conjugated forms of bile acids.
Differences in plasma metabolites during OGTT and graded intravenous glucose infusion will be
studied to assess information on possible regulation by the gut and the results will be
compared in subjects with normal glucose tolerance, impaired glucose tolerance and subjects
with type 2 diabetes mellitus.
Significance The expected results in this study will demonstrate that the gut plays an
important role in glucose homeostasis and that this system is dysregulated in type 2
diabetes. More importantly, novel factors derived or regulated from the gut that regulate
insulin resistance and glucose tolerance will be identified which could be possible targets
for future antidiabetic therapies.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
Completed |
NCT02226003 -
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
|
Phase 3 |